Raymond James Financial Services Advisors’s Nektar Therapeutics NKTR Stock Holding History

Raymond James Financial Services Advisors’s Portfolio NKTR Stock Details NKTR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-1,293	Closed	-$11K	–	3460
2023 Q4	$11K	Buy	+1,293	New	+$9.79K	﹤0.01%	3259
2020 Q1	–	Sell	-632	Closed	-$205K	–	2709
2019 Q4	$205K	Sell	632 -438	-41%	-$127K	﹤0.01%	2556
2019 Q3	$292K	Buy	1,070 +367	+52%	+$135K	﹤0.01%	2266
2019 Q2	$375K	Buy	703 +88	+14%	+$44.1K	﹤0.01%	2115
2019 Q1	$310K	Buy	615 +164	+36%	+$97.2K	﹤0.01%	2220
2018 Q4	$222K	Buy	451 +160	+55%	+$96.6K	﹤0.01%	2190
2018 Q3	$266K	Buy	291 +5	+2%	+$4.27K	﹤0.01%	2349
2018 Q2	$209K	Buy	286 +116	+68%	+$134K	﹤0.01%	2451
2018 Q1	$270K	Buy	+170	New	+$219K	﹤0.01%	2089

Other funds holding NKTR

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

MAM

Monaco Asset Management Monaco $1.26B AUM 60.23% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Raymond James Financial Services Advisors's NKTR Position: Q1 2024 in Review

Raymond James Financial Services Advisors sold out of Nektar Therapeutics (NKTR) in Q1 2024, closing a stake of 1,293 shares — an estimated $11K sold.

Raymond James Financial Services Advisors first reported a position in NKTR in Q1 2018 and held it in 9 quarters. The position peaked at $375K in Q2 2019. 124 funds tracked by Wall St. Rank hold NKTR as of Q1 2024.

Raymond James Financial Services Advisors reported no remaining Nektar Therapeutics position as of Q1 2024 after selling out during the quarter.
Raymond James Financial Services Advisors sold 1,293 Nektar Therapeutics shares in Q1 2024, an estimated $11K.
Raymond James Financial Services Advisors first reported a position in Nektar Therapeutics in Q1 2018 and held it in 9 quarters.
Raymond James Financial Services Advisors's Nektar Therapeutics position peaked at $375K in Q2 2019.
124 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q1 2024.

Based on Raymond James Financial Services Advisors's 13F filing for Q1 2024, filed 22 Apr 2024.